ArticleAnnals of the rheumatic diseases2007

Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?

Elisabeth Hjardem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.